Photo: Goleisureintl via Wikimedia Commons · CC BY 4.0
In July 2026, Adaptyx Biosciences presented at the American Diabetes Association’s annual meeting the first system able to continuously measure free cortisol in the skin. The stress hormone, historically hard to track outside a lab, could become the next major biomarker monitored by wearable devices, much as glucose became for diabetes over the past decade.
A patch that turns chemistry into data
The device relies on DNA aptamers: short, engineered strands of genetic material designed to recognize and bind specifically to cortisol molecules. As the hormone fluctuates in subdermal fluid, these aptamers flip electrical microswitches that generate a real-time readout. The patch packs up to 16 parallel channels, allowing the signal to be cross-checked with far more precision than a single-point sensor. In clinical trials, the system accurately tracked spikes following synthetic cortisol administration as well as natural hormonal rhythms, including overnight lows and morning peaks.
Why cortisol matters more than it seems
An estimated 25% of patients with difficult-to-control type 2 diabetes may have undiagnosed cortisol excess, a condition that worsens insulin resistance and complicates treatment. «We’re measuring the hormone that is literally at the core of your entire biology,» said endocrinologist Elena Christofides, who took part in evaluating the device. A continuous readout, instead of a single blood or saliva test, would let clinicians spot patterns that go unnoticed today and fine-tune treatment accordingly.
The first step toward full hormone monitoring
Adaptyx is not alone in this space; other efforts such as Level Zero Health, Biolinq, EnLiSense, Kilele Health and BioSens8 are also developing sensors for hormonal signals, though with different approaches, such as measuring cortisol through sweat rather than subdermal fluid. According to Jason Heikenfeld, a researcher at the University of Cincinnati, the technology is «a couple of years off» from wide market availability. For Adaptyx cofounder Alex Yoshikawa, cortisol is just the beginning: «We see cortisol as the stepping-stone for general hormone monitoring,» paving the way for sensors able to track multiple hormones simultaneously and in real time.
Advances like this confirm a broader trend: sensors that keep getting smaller and more precise, turning complex physical signals into instantly actionable data, whether inside the human body or across a fleet of vehicles and assets. If you’re curious how real-time sensor technology is also transforming fleet management, learn more at www.esencialgps.cl.
Based on data from IEEE Spectrum.
